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Abstract Perturbations in sarcomeric function may in
part underlie systolic and diastolic dysfunction of the
failing heart. Sarcomeric dysfunction has been ascribed to
changes in phosphorylation status of sarcomeric proteins
caused by an altered balance between intracellular kinases
and phosphatases during the development of cardiac
disease. In the present review we discuss changes in
phosphorylation of the thick ﬁlament protein myosin
binding protein C (cMyBP-C) reported in failing myocar-
dium, with emphasis on phosphorylation changes observed
in familial hypertrophic cardiomyopathy caused by muta-
tions in MYBPC3. Moreover, we will discuss assays which
allow to distinguish between functional consequences of
mutant sarcomeric proteins and (mal)adaptive changes in
sarcomeric protein phosphorylation.
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During recent years it has become increasingly evident that
cardiac cMyBP-C exerts an important role in the regulation
of sarcomere function with consequences for in vivo car-
diac performance. The functional role of cMyBP-C is
tightly regulated by kinase-mediated phosphorylation. The
most important kinase which is known to phosphorylate
cMyBP-C in vivo is protein kinase A (PKA), which is
activated upon stimulation of the b-adrenergic receptors
during increased stress as occurs during exercise. At the
sarcomere level, b-adrenergic receptor activation reduces
the sensitivity of myoﬁlaments to calcium, reduces passive
stiffness and increases the kinetics of cardiac contraction
due to PKA-mediated phosphorylation of the three sarco-
meric target proteins, cardiac troponin I (cTnI), titin,
and cMyBP-C. Although cTnI exerts a ‘‘dominant’’ role
in the reduction of myoﬁlament Ca
2?-sensitivity upon
PKA-mediated phosphorylation, recent studies indicated a
modulatory role for cMyBP-C in this process (Cazorla
et al. 2006; Cuello et al. 2011; Kooij et al. 2010b). The
most important regulatory role of cMyBP-C seems to be
the effect on cross-bridge kinetics of sarcomere contraction
(Stelzer et al. 2006a, 2006b). Involvement of cMyBP-C
and its phosphorylation in stretch activation has been
demonstrated in mice by Stelzer et al. (2006b, 2007).
This stretch activation might play an important role in
the development of systolic pressure (Steiger 1977; Stelzer
et al. 2006a). It has been proposed that cMyBP-C acts as a
structural constraint limiting cross-bridge formation and
that phosphorylation of cMyBP-C accelerates cross-bridge
kinetics which is required for enhanced rates of relaxation
and force development in diastole and systole, respectively.
cMyBP-C phosphorylation in end-stage heart failure
Systolic heart failure (SHF or heart failure with reduced left
ventricular ejection fraction) is the end-stage of various
cardiac diseases (e.g., ischemic heart disease, valve defects)
and is characterized by ineffective functioning of the heart
which then cannot supply sufﬁcient blood to meet the
body’s demands. The body tries to compensate for the
reduced cardiac output by sympathetic stimulation, in an
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heart rate and cardiac contractility. Because of the chronic
nature of the disease, this leads to a prolonged increase in
catecholamine levels in the serum. This in turn results in
the down-regulation and desensitization of the beta-
adrenergic receptor (Bristow et al. 1982) and reduced
phosphorylation of downstream PKA target proteins in the
end-stage failing heart (El-Armouche et al. 2004; Schw-
inger et al. 1999). In addition to reduced PKA signaling,
increased activity and expression of protein phosphatase 1
(PP1) has been reported in a swine model of post-myo-
cardial infarction (MI) cardiac remodeling (Duncker et al.
2009) as well as in patients with heart failure (Neumann
et al. 1997). PP1 dephosphorylates many PKA target pro-
teins and its activity is indirectly regulated by PKA via
phosphorylation of the PP1 inhibitor protein. In addition to
the changes in PP1 expression/activity, a decreased activity
of this endogenous inhibitor of PP1 was observed in heart
failure patients (El-Armouche et al. 2004).
In end-stage failing human myocardium, reduced
phosphorylation of all PKA sarcomeric target proteins
has been reported. Total phosphorylation of cTnI was
decreased in end-stage failing myocardium (Bodor et al.
1997; van der Velden et al. 2003; Zaremba et al. 2007).
This decrease could at least partially be attributed to
reduced PKA-mediated phosphorylation, as phosphoryla-
tion of the PKA-speciﬁc sites Ser23/24 was lower in failing
compared to non-failing donor heart tissue (Hamdani et al.
2010; Messer et al. 2007; van der Velden et al. 2006). In
addition, phosphorylation of the giant protein titin is
reduced in patients with systolic and diastolic heart failure
(Borbely et al. 2009; Kruger et al. 2009).
As indicated above, the other main target of PKA in the
sarcomere is cMyBP-C and in cardiac tissue from end-
stage heart failure patients its phosphorylation is also
decreased (El-Armouche et al. 2007; Jacques et al. 2008;
Zaremba et al. 2007), irrespective if the underlying cause
of heart failure (Copeland et al. 2010; Hamdani et al.
2010). Using 1D gel electrophoresis and staining with
the phospho-speciﬁc stain ProQ Diamond we observed
reduced phosphorylation of cMyBP-C in end-stage heart
failure patients with ischemic (ISHD) or idiopathic (IDCM)
cardiomyopathy (Fig. 1a). Protein phosphorylation can be
studied by a number of methods, one of which is 2D gel
electrophoresis. This technique is based on the iso-electric
point of a protein, which is reciprocally correlated to the
amount of phosphorylation. With this method, it was shown
that the cMyBP-C protein spots separated on the 2D gel
(Fig. 1b) were shifted to the basic side (higher pI) in failing
compared to donor cardiac samples in support for decreased
cMyBP-C phosphorylation in both ischemic and idiopathic
heart failure (Fig. 1c). Another method to quantitatively
study protein phosphorylation is by phosphate afﬁnity gel
electrophoresis, in which the degree of phosphorylation
is inversely related to the migration speed in the gel
(Kinoshita et al. 2006). In human donor heart tissue, it was
shown that most of the cMyBP-C exists in mono-, bi-, tri-,
or tetra-phosphorylated forms with very little of the
unphosphorylated form, while in hearts from end-stage
heart failure patients the unphosphorylated form is pre-
dominant, with only some mono-phosphorylated cMyBP-C
(Copeland et al. 2010). Protein phosphorylation can also be
studied by using phosphorylation site-speciﬁc antibodies.
cMyBP-C can be phosphorylated in vivo on at least three
sites, all of which are located in the cardiac isoform speciﬁc
M region, i.e., Ser273, Ser282, and Ser 302 (Bareﬁeld and
Sadayappan 2010). At least one other site should exist in
humans (Copeland et al. 2010) and multiple sites are pre-
dicted from studies in animal models (Yuan et al. 2006)o r
on the basis of in vitro studies (Jia et al. 2010). Using
antibodies speciﬁc for these sites, it was shown that Ser282
phosphorylation was markedly reduced in end-stage failing
heart tissue (El-Armouche et al. 2007), as was phosphory-
lation of Ser273 and Ser302 (Copeland et al. 2010).
cMyBP-C in familial hypertrophic cardiomyopathy
(FHCM)
Another class of cardiac disease consists of the inherited
cardiomyopathies (Watkins et al. 2011). In these forms
of cardiomyopathy, cardiac dysfunction, and altered
morphology are caused by genetic mutations rather than an
external cause, such as coronary artery disease or hyper-
tension. FHCM is the most prevalent inherited cardiac
disease and has a prevalence of 1:500 (Maron 2004).
FHCM is most frequently caused by mutations in genes
coding for sarcomeric proteins (Richard et al. 2003).
Interest in cMyBP-C grew when it became apparent
that *40% of the FHCM causing mutations were located
in the MYBPC3 gene (Richard et al. 2003).
The sarcomeric phosphorylation pattern in HCM shows
a great deal of overlap with that in heart failure. Similar to
heart failure samples, phosphorylation of cTnI was found
to be reduced in FHCM (Hoskins et al. 2010; van Dijk et al.
2008; van Dijk et al. 2009b). Cardiac MyBP-C phosphor-
ylation was also lower in FHCM patients (Hoskins et al.
2010; Jacques et al. 2008; van Dijk et al. 2008; van Dijk
et al. 2009b), and Copeland et al. (2010) showed a
shift towards unphosphorylated and mono-phosphorylated
cMyBP-C similar to end-stage failing myocardium.
The lower cMyBP-C phosphorylation in FHCM hearts was
found in patients in whom no mutation was found in the
genes coding for cMyBP-C, b-myosin heavy chain and
troponin T. Figure 2a shows protein data from patients
(NYHA class II) who underwent myectomy surgery to
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samples of end-stage failing FHCM patients. In the Neth-
erlands two founder mutations in MYBPC3 account for
35% of all HCM mutations (Alders et al. 2003). Although
these mutations are predicted to result in truncated
proteins, no mutant protein was found, indicating haplo
insufﬁciency rather than a toxic peptide as the cause of
FHCM (van Dijk et al. 2009a). In this patient population
cMyBP-C protein levels were 33% lower than donor levels,
but surprisingly relative phosphorylation of cMyBP-C was
not different between patients and donors, whereas cTnI
phosphorylation was notably reduced (van Dijk et al.
2009a) (Fig. 2b). The observation that cMyBP-C phos-
phorylation was similar in patients with MYBPC3 muta-
tions compared to donors may be explained by an altered
stoichiometry between kinase activities in the cardiac cells
and cMyBP-C protein levels. The reduction in cMyBP-C
protein level may match the reduction in kinase activities
in FHCM with MYBPC3 mutations.
In both end-stage failing and most FHCM hearts
phosphorylation was markedly lower than in donor hearts.
It has been debated whether donor hearts truly represent
the normal situation and can therefore be used as controls
(Jweied et al. 2007; Marston and de Tombe 2008). Espe-
cially the fact that many donors receive positive inotropic
support and may have brain damage leading to a cate-
cholamine surge is of concern to studies of protein phos-
phorylation, as these conditions would lead to enhanced
PKA activity. Furthermore, it has recently been shown
that different tissue procurement strategies can affect the
phosphorylation of sarcomeric proteins (Walker et al.
2011). Noteworthy, in the latter study cMyBP-C phos-
phorylation did not change with different procurement
strategies.
The observation that cMyBP-C is less phosphorylated
in a host of different cardiac disease states does not
directly establish the functional consequences of lower
phosphorylation of cMyBP-C. To study the functional
consequences of cMyBP-C phosphorylation, either trans-
genic animal models can be used or studies can be
performed by modulating phosphorylation in vivo or in
vitro.
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Fig. 1 Cardiac MyBP-C phosphorylation in end-stage heart failure.
a Samples from donor, end-stage heart failure patients with IDCM
or ISHD cardiomyopathy were analyzed for cMyBP-C and cTnI
phosphorylation with ProQ Diamond stained gels and normalized to
total SYPRO-stained cMyBP-C. Phosphorylation of cardiac cMyBP-
C and cTnI is higher in donor compared to the ISHD and IDCM
samples. Phosphorylation in the groups was normalized to donor,
which was set to one. Figure adapted from Hamdani et al. (2010)
with kind permission from Springer Science ? Business Media.
b Representative 2D-gels from donor and IDCM, showing a shift of
cMyBP-C towards higher pI spots (left) in IDCM compared with
donor, indicating less phosphorylation. Figure adapted from Copeland
et al. (2010) with permission from Elsevier. c Quantiﬁcation of the
different spots from 2D gel analysis showing similar shifts in cMyBP-
C phosphorylation in IDCM and ISHD compared to donor. *P\0.05
versus donor in one-way ANOVA followed by post-test Bonferroni;
#P\0.05 versus IDCM in one-way ANOVA followed by post-test
Bonferroni analysis
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The effects of cMyBP-C phosphorylation on its physio-
logical function have been demonstrated with transgenic
animal models. It has been established that cMyBP-C is
vital for normal cardiac performance as complete knock-
out of cMyBP-C (Carrier et al. 2004; Harris et al. 2002)o r
homozygous expression of a mutated MYBPC3 gene,
resulting in less than 10% expression of truncated cMyBP-
C (McConnell et al. 1999; Sadayappan et al. 2005), both
led to a dilated and dysfunctional heart with cardiomyocyte
disarray and ﬁbrosis. Sadayappan and colleagues provided
evidence that apart from cMyBP-C expression level also its
phosphorylation is essential for cardiac performance. They
showed that transgenic expression of wild-type cMyBP-C
could rescue the phenotype of mice carrying homozygous
mutated MYBPC3, while expression of cMyBP-C protein
in which the three well-known phosphorylation sites
(Ser273, 282, and 302) were replaced by unphosphorylat-
able alanines (cMyBP-C
AllP-) did not correct dysfunction
(Sadayappan et al. 2005). Furthermore, transgenic expres-
sion of cMyBP-C in which the known phosphorylation
sites were replaced by the negatively charged aspartic acid
(cMyBP-C
AllP?), to mimic constitutive tri-phosphoryla-
tion, was able to rescue the phenotype of the null mutant
(Sadayappan et al. 2006). Cardiomyocytes isolated from
cMyBP-C
AllP- mice showed a reduced stretch activation
after PKA treatment compared to mice expressing wild-
type cMyBP-C (Tong et al. 2008). In addition, the hearts of
these animals showed an attenuated dobutamine-induced
(Dob) contractile reserve compared with animals express-
ing the wild-type protein. To further elucidate the role
of the individual phosphorylation sites in cMyBP-C,
Sadayappan et al. (2011) used a transgenic mouse model
in which the Ser282 site was either converted to an
alanine or to an aspartic acid and bred into the cMyBP-C
null mutant. This revealed that phosphorylation of the
Ser302 depends on Ser282 phosphorylation, while the
Dob-induced increase in cardiac contractility was depen-
dent on all three sites being phosphorylated (Sadayappan
et al. 2011). Taken together this illustrates the vital role of
cMyBP-C phosphorylation for its physiological function
and a proper cardiac performance.
Phosphorylation of cMyBP-C is not only important in
contraction, but also seems to exert a protective effect
against protein degradation as a canine model of low ﬂow
ischemia showed cMyBP-C dephosphorylation and degra-
dation (Decker et al. 2005). Similar degradation was seen
in a mouse model of ischemia–reperfusion, in which
cMyBP-C was protected against degradation in mice with
cMyBP-C
AllP? (Sadayappan et al. 2006). cMyBP-C
AllP?
also protected against ischemia–reperfusion injury, as the
ischemic area and apoptosis were reduced and fractional
shortening was increased compared with wild-type
cMyBP-C (Sadayappan et al. 2006, 2009).
Modulation of cMyBP-C phosphorylation
Kinases
To establish which kinases are responsible for cMyBP-C
phosphorylation, both in vivo and in vitro studies have
been used. The ﬁrst clue that PKA could phosphorylate
cMyBP-C was the observation that phosphorylation of
cMyBP-C was increased after beta-adrenergic receptor
stimulation in rat hearts (Jeacocke and England 1980) and
frog atria (Hartzell and Titus 1982). In a follow-up study
it was shown that PKA could phosphorylate isolated
A 
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Fig. 2 Cardiac MyBP-C phosphorylation in FHCM. a Phosphoryla-
tion status of cMyBP-C and cTnI was assessed by ProQ Diamond
stained gels and signal was normalized to the SYPRO Ruby stained
cMyBP-C and a-actinin band respectively as described before
(Zaremba et al. 2007). Phosphorylation status of cMyBP-C and cTnI
was lower in cardiac tissue obtained from myectomy operation from
FHCM patients (NYHA class II) and in cardiac tissue obtained from
explanted hearts from end-stage FHCM patients (NYHA class IV)
compared to donor samples. Phosphorylation in the groups was
normalized to donor, which was set to one. b In a subgroup of FHCM
patients with MYBPC3 mutations (MYBPC3mut), the phosphorylation
status of cMyBP-C was similar between FHCM and donor samples,
while cTnI phosphorylation was lower. Phosphorylation was normal-
ized to donor, which was set to one. *P\0.05 versus donor in one-
way ANOVA followed by post-test Bonferroni analysis. Figure
adapted from van Dijk et al. (2009a) with permission
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PKA incubation of skinned cardiomyocytes from end-stage
failing heart tissue showed a shift towards cMyBP-C forms
with a lower iso-electric point (increased pH) on 2D
gel electrophoresis, indicating increased phosphorylation
(Fig. 3a, b). In vitro phosphorylation of isolated cMyBP-C
by PKA in the presence of [
32P] ATP, followed by prote-
olysis and sequencing could pinpoint the three phosphor-
ylation sites to the cardio-speciﬁc region between the C1
and C2 domains of the protein (Gautel et al. 1995;
Mohamed et al. 1998). Functionally it was found that
phosphorylation of cMyBP-C with PKA lead to changes in
thick ﬁlament structure and an increased level of weakly
bound cross-bridges at low Ca
2?-levels, which could lead
to increased force generating cross-bridges during systole
(Levine et al. 2001).
An area that has received a lot of attention in the last
years, is the compartmentalization of PKA signaling, which
enhances its speciﬁcity. This spatial regulation is mediated
by so-called A-kinase anchoring proteins (AKAPs) that
bind PKA and are able to localize to speciﬁc subcellular
compartments (Fink et al. 2001; Ruehr et al. 2004). The thin
ﬁlament protein troponin T has been identiﬁed as a
sarcomeric AKAP, which provides a pool of PKA that can
quickly phosphorylate myoﬁlament proteins upon activa-
tion (Sumandea et al. 2011). Recently, myomegalin was
shown to interact with cMyBP-C and act as an AKAP (Uys
et al. 2011).
To test the role of PKA-mediated cMyBP-C phosphor-
ylation in cardiac pathology, phosphorylation changes were
studied in remodeled myocardium of swine 3 weeks after
MI at baseline and upon in vivo administration of the
beta-adrenergic receptor agonist Dob (Boontje et al. 2011;
Duncker et al. 2009). At baseline there were no differences
in cMyBP-C and cTnI phosphorylation in the post-MI
animals compared with sham operated animals (Fig. 3c, d).
Dob administration had a discordant effect on the PKA
targets, as the increase in cTnI phosphorylation was
markedly attenuated in the post-MI hearts compared to
sham, while cMyBP-C was not different between post-MI
C D
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Fig. 3 PKA-mediated cMyBP-
C phosphorylation in vitro and
in vivo. a 2D-gel analysis of
cMYBP-C from IDCM
myocardium before and after
PKA treatment, showing an
shift towards lower pI species,
indicating increased
phosphorylation.
b Quantiﬁcation of the changes
in phosphorylation after PKA
treatment. c, d Effect of high
and low dose Dob
administration (2 and 10 lg/kg/
min; Dob2 and Dob10) on the
phosphorylation of the PKA-
speciﬁc Ser23/24 cTnI site
(n = 5) and Ser282 cMyBP-C
site (n = 6) in sham and post-
MI remodeled myocardium
from pigs. cTnI phosphorylation
increased signiﬁcantly in sham
animals but this increase was
attenuated in MI animals.
cMyBP-C was not different
between MI and sham animals.
Figure adapted from Boontje
et al. (2011) with permission
from Elsevier. *P\0.05, effect
of Dob in a 1-way ANOVA
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an increased activation of Ca
2?-dependent calmodulin
kinase II (CaMKII) in post-MI myocardium (Boontje et al.
2011).
Calmodulin kinase II was ﬁrst found to phosphorylate
cMyBP-C as a Ca
2?-calmodulin dependent kinase co-
puriﬁed with cMyBP-C isolated from chicken hearts
(Hartzell and Glass 1984), which was subsequently iden-
tiﬁed as CaMKII (Schlender and Bean 1991). Whereas
PKA could add 3 mol of phosphates per mole of cMyBP-
C, CaMKII could add only one (Gautel et al. 1995). Fur-
thermore, it seems that the site now identiﬁed as Ser282 is
the target site for CaMKII (Gautel et al. 1995) and that
this site needs to be phosphorylated ﬁrst to facilitate
phosphorylation of Ser302 (Sadayappan et al. 2011). Func-
tionally, CaMKII phosphorylation seems to be important
in the frequency-dependent increase in force as this was
depressed in intact muscle treated with a CaMKII inhibitor
(Tong et al. 2004).
Protein kinase C can also phosphorylate cMyBP-C, as
revealed by in vitro phosphorylation studies with recom-
binant PKC in vitro (Lim et al. 1985; Venema and Kuo
1993) or by PKC stimulation in intact cardiomyocytes
(Venema and Kuo 1993). The phosphorylation sites of
PKC on cMyBP-C overlap with those of PKA, as two of
the three PKA-sites were also phosphorylated by PKC
(Mohamed et al. 1998). PKC incubation combined with
phosphorylation site-speciﬁc antibodies revealed that
Ser273 and Ser302 are PKC target sites (Sadayappan et al.
2011). Protein kinase C is composed of a family of kinases,
of which in the heart PKC-a is known to be upregulated in
heart failure (Bowling et al. 1999). To study the effect of
different PKC isoforms on cMyBP-C and cTnI phosphor-
ylation, incubations with PKC-a and the novel–non Ca
2?-
activated-PKC-e in skinned cardiomyocytes from failing
tissue were performed (Kooij et al. 2010a). Both isoforms
could phosphorylate cMyBP-C and cTnI, albeit with
different substrate afﬁnities (Fig. 4). Phosphorylation of
cMyBP-C by another isoform of PKC, namely PKCf,
was shown by expressing a constitutively active form in
cardiomyocytes (Wu and Solaro 2007). PKC phosphory-
lation of cMyBP-C is proposed to cause a decrease in
actomyosin ATPase, which could be cardioprotective (Pyle
et al. 2003).
Recently, Protein kinase D (PKD) and p90 ribosomal S6
kinase (p90 RSK or RSK) are added to the gamut of
kinases able to phosphorylate cMyBP-C. PKD phosphor-
ylates cTnI at the same sites as PKA (Haworth et al. 2004),
while it phosphorylates cMyBP-C only at Ser302 (Bard-
swell et al. 2010). RSK on the other hand phosphorylates
cMyBP-C at Ser-282 (Cuello et al. 2011). Phosphorylation
of cMyBP-C with RSK was accompanied by a reduction in
Ca
2?-sensitivity of force development and acceleration of
cross-bridge kinetics, independent from cTnI phosphory-
lation (Cuello et al. 2011).
Phosphatases
In contrast to the extensive body of work published about
kinase-mediated phosphorylation of cMyBP-C, only a
limited number of studies have focused on the effects
of phosphatases. As was mentioned above, cardiac PP1
expression and activity is increased in heart failure
(Neumann et al. 1997). Puriﬁed cMyBP-C that was ﬁrst
phosphorylated by PKA, was subsequently dephosphoryl-
ated by 30–40% by incubation with the catalytic subunit of
PP1 (Schlender et al. 1987). The same extent of dephos-
phorylation was seen after incubation of skinned donor
heart tissue with PP1 (Yang et al. 2008; Zaremba et al.
2007) as well as in skinned mice cardiomyocytes (Yang
et al. 2008). Incubations of donor tissue with a high con-
centration of PP1 resulted in almost complete dephospho-
rylation of cTnI, while cMyBP-C dephosphorylation was
moderate (Fig. 5). PP1 incubations led to the decrease of
the tri- and tetra-phosphorylated cMyBP-C and an increase
in the unphosphorylated form (Copeland et al. 2010).
Functionally, PP1 incubation in donor tissue resulted in a
marked increase in the Ca
2?-sensitivity of force develop-
ment, which could be reversed by subsequent PKA incu-
bation (Neulen et al. 2007). Although in another study, PP1
incubation had no effect on Ca
2?-sensitivity in donor cells,
but increased Ca
2?-sensitivity after pre-incubation with
PKC (Belin et al. 2007). The effect of PP1 on Ca
2?
-sensitivity is likely explained by the dephosphorylation of
TnI, rather than cMyBP-C phosphorylation (Duncker et al.
2009).
α
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Fig. 4 Phosphorylation of cTnI and cMyBP-C by protein kinase C.
Phosphorylation of cMyBP-C and cTnI after incubation of failing
tissue samples with PKCa (n = 5) or PKCe (n = 2). Phosphorylation
was assessed by ProQ Diamond stained gels and normalized to total
SYPRO-stained cMyBP-C. Both PKC isoforms increased phosphor-
ylation of cMyBP-C and cTnI, albeit with different speciﬁcities.
*P\0.05 versus baseline. BL baseline. Figure adapted from (Kooij
et al. 2010a) with permission
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phatase that is commonly used for in vitro dephosphoryl-
ation assays. AP mainly dephosphorylates troponin T in the
sarcomere, while cMyBP-C and TnI are signiﬁcantly but
to a lesser degree dephosphorylated (Kooij et al. 2010a;
Zaremba et al. 2007) (Fig. 5). Functionally, incubation of
myoﬁlaments from donor hearts with AP leads to a slight,
but signiﬁcant increase in Ca
2?-sensitivity of force devel-
opment and passive force (Kooij et al. 2010a), but the role
of cMyBP-C dephosphorylation herein is unclear.
Protein phosphatase 2a (PP2a) is able to dephosphory-
late cMyBP-C (Schlender et al. 1987), although incubation
of skinned cardiomyocytes with PP2a showed only a low
degree of cMyBP-C dephosphorylation (Zaremba et al.
2007). A proteomic study on rat cardiomyocytes showed
that the PP2a regulatory subunit B56a, is present in the
myoﬁlaments after skinning and that B56a level decreases
after b-adrenergic receptor stimulation (Yin et al. 2010).
PP2a’s sarcomeric localization is regulated via its inter-
action with P
21-activated kinase-1 (PAK1) (Sheehan et al.
2007). Cultured cardiomyocytes with increased PAK1
activity and thus sarcomeric localization of PP2a, had
lower phosphorylation of cMyBP-C and cTnI (Ke et al.
2004). Conﬂicting data is published about the effect of
PP2a incubation on skinned cardiomyocytes. While Belin
et al. (2007) found no changes on myoﬁlament function
in either non-failing or failing rat cardiac tissue incubated
with PP2a, a recent paper by Wijnker et al. (2011) showed
an increased Ca
2?-sensitivity of force development in
skinned cardiomyocytes isolated from human donor
hearts, but not from end-stage failing hearts. This effect
was attributed to dephosphorylation of cTnI, as PP2a did
not dephosphorylate cMyBP-C (Wijnker et al. 2011).
Further research is warranted to see if cMyBP-C is a target
of PP2a in vivo.
Employing kinases and phosphatases to speciﬁcally
phosphorylate or dephosphorylate cMyBP-C should help
to distinguish between functional consequences of mutant
sarcomere proteins and (mal)adaptive changes in sarco-
meric protein phosphorylation. While a number of kinases
have been identiﬁed that readily could phosphorylate
cMyBP-C, no speciﬁc phosphatase has been found that can
dephosphorylate cMyBP-C to a large extent. Whether
dephosphorylation pathways play a role in modulating the
(patho)physiological role of cMyBP-C warrants further
study.
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